Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for rare and vision-threatening ocular diseases, primarily within the ophthalmology and oncology industries. The company’s core mission is to preserve vision and life by treating eye cancers using precision biologics that selectively target diseased cells while minimizing damage to healthy ocular tissue.
The company’s lead and currently primary asset is AU-011 (belzupacap sarotalocan), a novel virus-like drug conjugate designed for the treatment of early-stage choroidal melanoma. Aura Biosciences is uniquely positioned in the niche field of ocular oncology through its proprietary platform that combines targeting moieties with phototoxic payloads activated by light. Founded in 2009, the company has evolved from early academic research into a publicly traded biotechnology firm following its initial public offering in 2021, advancing its lead program into late-stage clinical development.
Business Operations
Aura Biosciences operates as a single-reportable-segment biotechnology company, generating no commercial revenue to date and focusing primarily on research and development activities. Its business model centers on the discovery, clinical development, and potential future commercialization of targeted therapies for ocular cancers, with expenditures primarily related to clinical trials, manufacturing of clinical-grade materials, and regulatory activities.
The company conducts clinical trials in both the United States and international markets, leveraging a network of academic medical centers and ophthalmic oncology specialists. Aura Biosciences controls proprietary technology related to its virus-like drug conjugate platform and retains global rights to its lead product candidate. As of publicly available disclosures, the company does not rely on material joint ventures for its core programs and operates without significant commercial partnerships, instead maintaining internal oversight of development strategy.
Strategic Position & Investments
Aura Biosciences’ strategic direction is centered on advancing AU-011 (belzupacap sarotalocan) through late-stage clinical development for early-stage choroidal melanoma, with the goal of offering a vision-sparing alternative to existing therapies such as radiotherapy or enucleation. The company has invested heavily in clinical trials designed to demonstrate both efficacy and ocular safety, positioning the therapy as a potential first-line treatment.
Beyond its lead indication, Aura Biosciences has indicated that its underlying platform technology may be applicable to additional ocular and retinal diseases, although these programs remain in earlier stages of evaluation. The company has not disclosed a broad portfolio of subsidiaries or acquired companies, and its capital investments have primarily supported internal research, clinical development, and manufacturing scale-up rather than external acquisitions.
Geographic Footprint
Aura Biosciences is headquartered in Cambridge, Massachusetts, a major biotechnology hub within the United States. Its corporate, research, and administrative operations are primarily based in this region, benefiting from proximity to academic institutions, clinical collaborators, and life sciences infrastructure.
Operationally, the company maintains a global clinical footprint through trial sites across North America and Europe, reflecting the international prevalence of its target indications and the need for diverse patient enrollment. While Aura Biosciences does not currently operate commercial facilities abroad, its clinical and regulatory activities give it an expanding international presence in preparation for potential future commercialization.
Leadership & Governance
Aura Biosciences is led by an executive team with experience across biotechnology, ophthalmology, and drug development, emphasizing scientific rigor, disciplined capital allocation, and a patient-centric development philosophy. The leadership team guides the company’s strategy with a focus on advancing innovative therapies for underserved ocular diseases while navigating regulatory and clinical complexities.
Key executives include:
- Elisabet de los Pinos – President and Chief Executive Officer
- Jill Carroll – Chief Financial Officer
- Terrance McGuire – Chief Operating Officer
- Pablo J. Cagnoni – Chief Medical Officer
- Richard L. Glickman – Chief Scientific Officer
The board and executive leadership collectively emphasize long-term value creation through focused development of differentiated assets and adherence to strong governance practices aligned with public company standards.